Genomic Testing

The study is being conducted as part of the landmark ProtecT trial.

According to the authors, these findings support the early use of genomic testing to guide treatment decisions.

As the year comes to a close, we revisit some of this year’s top content on genomic testing.

Kenneth G. Nepple, MD, discusses a quality improvement initiative focused on identifying patients with prostate cancer who may be eligible for genetic testing.

The PROSTOX ultra test identifies men with localized prostate cancer who are at a higher risk of developing late GU toxicity from radiation, helping to inform treatment decisions.

Patients with GG1 disease and a high genomic classifier score had a significantly higher risk of disease progression.

Overall, germline pathogenic variants were common, identified in approximately 1 in 7 tested patients.

The approval is supported by data from the phase 3 AMPLITUDE trial.

The PROSTOX ultra test can predict which patients with localized prostate cancer are at a higher risk of GU toxicity from SBRT.

Veda N. Giri, MD, outlines alternative care delivery models that could help improve access to genetic testing for prostate cancer.

Veda N. Giri, MD, outlines some of the key barriers to genetic testing in prostate cancer.

Veda Giri, MD, outlines points of consensus and areas of disagreement across national and international guideline recommendations for germline testing in prostate cancer.

Veda Giri, MD, highlights her recent review publication on the current state of germline testing in prostate cancer.

Hong Truong, MD, MS, details key findings on referrals for genetic counseling among patients with kidney cancer who meet the criteria for genetic evaluation.

Rana R. McKay, MD, FASCO, outlines findings from a study looking at the somatic, germline, and immunologic landscapes of UTUC and UCB tumors.

Hong Truong, MD, MS, highlights key findings on genetic counseling rates in patients with kidney cancer.

The findings were derived from the multicenter, prospective, phase 3 STAMPEDE trial.

Kathryn H. Gessner, MD, PhD, outlines the clinical scenarios in which she finds genomic testing most useful.

The study found differences in genomic alteration frequencies between non-Hispanic Black and non-Hispanic White veterans with metastatic prostate cancer, but showed similar survival outcomes.

“I truly think genetic testing should be incorporated as a part of daily care in prostate cancer,” says Joy Maulik, CRNP.

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

WNT9B E152K was associated with a 2.5-fold increase in the risk of prostate cancer and reached genome-wide significance.

"[The] full integration [of genomic classifier tests] into clinical practice requires additional research to better understand their cost-effectiveness, clinical utility, and impact on diverse populations," says Amir Alishahi Tabriz, MD, PhD, MPH.

Test your knowledge of these often-overlooked but essential aspects of genetic and genomic testing.